Cambridge, Massachusetts, U.S., September 21, 2026
Sensorium Therapeutics, a clinical-stage central nervous system biotechnology company, has announced positive Phase 1a clinical data for SNTX-2643, its investigational state-selective serotonin transporter (SERT) modulator being developed for social anxiety disorder (SAD) and generalized anxiety disorder (GAD). The results showed that a single 3 mg dose produced measurable CNS pharmacodynamic activity within approximately two hours, with effects remaining evident at 24 hours. The findings were presented at Psych Congress 2026 in New Orleans and included safety, pharmacokinetic and exploratory pharmacodynamic assessments in healthy adults. Sensorium reported that SNTX-2643 was generally well tolerated, demonstrated predictable pharmacokinetics and showed no clinically significant food effect. In an exploratory target-engagement cohort, the investigational therapy attenuated brain responses to an experimentally induced psychological stressor at both two and 24 hours, while complementary autonomic responses were also observed. The company emphasized that these early findings are exploratory and do not establish clinical efficacy in patients with anxiety disorders.
SNTX-2643 Shows Rapid CNS Pharmacodynamic Activity
The Phase 1a study enrolled 63 healthy adults and included single-ascending-dose cohorts, a randomized double-blind placebo-controlled target-engagement cohort and an open-label food-effect cohort. The target-engagement portion included 25 participants, with 15 receiving a single 3 mg dose of SNTX-2643 and 10 receiving placebo. Quantitative electroencephalography, or qEEG, was used as an exploratory measure of brain activity. Following administration of SNTX-2643, researchers observed changes in resting-state brain activity beginning at approximately two hours and continuing through 24 hours. The treatment increased beta activity and reduced relative delta activity, a pattern that Sensorium said was more consistent with cortical activation rather than sedation. The company reported that multiple findings remained nominally significant after adjustment for the number of EEG comparisons, although the analyses were exploratory and were not designed to measure clinical efficacy.
The study also incorporated an experimentally controlled psychological stress challenge using aversive videos designed to produce measurable anxiety-related physiological and neurological responses. Participants receiving placebo showed marked increases in beta and gamma EEG activity during the challenge, while a single 3 mg dose of SNTX-2643 significantly attenuated these responses at both two and 24 hours. Additional analyses indicated attenuation of stress-associated cortical activity without broad suppression of total EEG activity. Complementary autonomic measures also showed directional changes, including reduced heart rate and increased heart-rate variability at two hours, with similar directional effects observed at 24 hours.
Pharmacodynamic Effects Persist as Drug Exposure Falls
Advertisement
One notable finding involved the persistence of pharmacodynamic activity despite declining plasma exposure. Mean plasma concentrations of SNTX-2643 were approximately 6.0 ng/mL two hours after the 3 mg dose and declined to approximately 0.6 ng/mL at 24 hours. Despite this substantial reduction in systemic exposure, separation from placebo during the stress challenge remained evident at 24 hours. Sensorium said this observation suggests the possibility of durable pharmacodynamic effects beyond peak systemic exposure, although additional studies will be required to determine the mechanism, duration and clinical relevance of the finding. Higher doses than 3 mg are planned for future evaluation. Safety and pharmacokinetic findings from the study were also favorable. SNTX-2643 was generally well tolerated, with most treatment-emergent adverse events described as mild and transient. No serious adverse events, deaths or discontinuations due to adverse events were observed. The study found no clinically significant findings in laboratory assessments, electrocardiograms or physical examinations. The median time to peak plasma concentration was approximately 1.5 to two hours, while the median half-life was approximately four to six hours. Food did not have a clinically significant effect on drug exposure. Exploratory assessments of attention, information processing and perceptual judgment did not identify clinically significant impairment associated with the observed CNS pharmacodynamic effects.
Sensorium Advances Novel Anxiety Drug Program
SNTX-2643 is the lead investigational therapy from Sensorium’s SENS-01 program and is being developed for SAD and GAD, with potential applicability across additional CNS disorders. The company describes the molecule as a state-selective serotonin modulator designed to produce rapid onset while potentially reducing off-target effects and tolerability concerns associated with some existing anxiolytic approaches. The Phase 1a study was primarily designed to characterize safety, tolerability, pharmacokinetics and pharmacodynamics in healthy volunteers and to inform subsequent clinical studies.
The Phase 1a findings provide early human evidence that SNTX-2643 can produce measurable CNS target engagement and pharmacodynamic effects following a single dose. However, because the study involved healthy participants and exploratory neurological endpoints, further clinical trials will be needed to determine whether these biological signals translate into meaningful improvements for people living with anxiety disorders. Sensorium’s next development steps are expected to further investigate the compound’s mechanism, dose-response relationship, duration of pharmacodynamic activity and potential clinical effects.
Source: Sensorium Therapeutics press release
